series-b
Stage
2
Investors
About
Artiva is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for autoimmune diseases, with a lead product candidate, AlloNK®, currently in multiple clinical trials.
Explore Artiva's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.